Janus Henderson Group PLC Grows Stake in Global Blood Therapeutics Inc (GBT)

Janus Henderson Group PLC increased its stake in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 43.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,415,558 shares of the company’s stock after purchasing an additional 431,325 shares during the period. Janus Henderson Group PLC owned approximately 3.24% of Global Blood Therapeutics worth $43,953,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GBT. Bank of America Corp DE raised its holdings in shares of Global Blood Therapeutics by 103.6% during the first quarter. Bank of America Corp DE now owns 7,141 shares of the company’s stock valued at $263,000 after purchasing an additional 3,633 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Global Blood Therapeutics by 53.0% during the second quarter. Russell Investments Group Ltd. now owns 44,014 shares of the company’s stock valued at $1,203,000 after purchasing an additional 15,253 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Global Blood Therapeutics by 35.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 149,634 shares of the company’s stock valued at $4,093,000 after purchasing an additional 38,829 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Global Blood Therapeutics during the second quarter valued at approximately $211,000. Finally, Rhumbline Advisers raised its holdings in shares of Global Blood Therapeutics by 118.5% during the second quarter. Rhumbline Advisers now owns 41,801 shares of the company’s stock valued at $1,143,000 after purchasing an additional 22,670 shares during the last quarter. 90.48% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald set a $61.00 price objective on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Monday, December 11th. HC Wainwright set a $73.00 price objective on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Monday, December 11th. Nomura boosted their price objective on shares of Global Blood Therapeutics to $91.00 and gave the company a “buy” rating in a report on Monday, December 11th. BidaskClub upgraded shares of Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 12th. Finally, Oppenheimer set a $79.00 target price on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Tuesday, December 12th. One analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Global Blood Therapeutics currently has a consensus rating of “Buy” and an average price target of $62.07.

In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the transaction, the insider now directly owns 140,055 shares in the company, valued at $4,201,650. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Charles J. Homcy sold 70,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $33.97, for a total transaction of $2,377,900.00. Following the completion of the transaction, the director now owns 83,328 shares of the company’s stock, valued at $2,830,652.16. The disclosure for this sale can be found here. Insiders have sold 88,500 shares of company stock valued at $3,003,350 over the last 90 days. 5.30% of the stock is currently owned by company insiders.

Shares of Global Blood Therapeutics Inc (GBT) opened at $36.80 on Tuesday. Global Blood Therapeutics Inc has a 12-month low of $13.35 and a 12-month high of $45.85.

Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.04). During the same quarter in the prior year, the company posted ($0.58) EPS. equities analysts forecast that Global Blood Therapeutics Inc will post -2.55 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/12/19/janus-henderson-group-plc-grows-stake-in-global-blood-therapeutics-inc-gbt.html.

Global Blood Therapeutics Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply